Supraspinal modulation of pain by cannabinoids: The role of GABA and glutamate

British Journal of Pharmacology

Volumn 152, Issue 5, 2007, Pages 633-648

  Rea, K ^a   Roche, M ^a   Finn, D P ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Brain; Cannabinoids; GABA; Glutamate; Neurotransmission; Nociception; Pain

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR ANTAGONIST; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; GLUTAMIC ACID; METHYLARACHIDONOYLFLUOROPHOSPHONATE; RIMONABANT; UNCLASSIFIED DRUG; URB 602;

GABAERGIC TRANSMISSION; HUMAN; HYPOTHALAMUS; INFLAMMATION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; REVIEW; SPINAL CORD; THALAMUS;

ANIMALS; BRAIN; ENDOCANNABINOIDS; GAMMA-AMINOBUTYRIC ACID; GLUTAMATES; HUMANS; MODELS, BIOLOGICAL; NEURONS; PAIN; SCIATIC NEUROPATHY;

EID: 35648993556     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707440     Document Type: Review

References (188)

1. Acquas E, Pisanu A, Marrocu P, Di Chiara G (2000). Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo. Eur J Pharmacol 401: 179-185.
2. Acquas E, Pisanu A, Marrocu P, Goldberg SR, Di Chiara G (2001). Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study. Eur J Pharmacol 419: 155-161.
3. Auclair N, Otani S, Soubrie P, Crepel F (2000). Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J Neurophysiol 83: 3287-3293.
4. Azad SC, Eder M, Marsicano G, Lutz B, Zieglgansberger W, Rammes G (2003). Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn Mem 10: 116-128.
5. Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S et al. (2006). CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 23: 1530-1538.
6. Beltramo M, Piomelli D (2000). Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. NeuroReport 11: 1231-1235.
7. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997). Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277: 1094-1097.
8. Bleakman D, Alt A, Nisenbaum ES (2006). Glutamate receptors and pain. Semin Cell Dev Biol 17: 592-604.
9. Bodor AL, Katona I, Nyiri G, Mackie K, Ledent C, Hajos N et al. (2005). Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci 25: 6845-6856.
10. Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyauchi H et al. (2000). Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA 97: 5044-5049.
11. Bouaboula M, Poinot-Chazel C, Bourrie B, Canat X, Calandra B, Rinaldi-Carmona M et al. (1995). Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312: 637-641.
12. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D (2006). Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 10: 287-333.
13. Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60: 155-163.
14. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC et al. (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 396: 141-149.
15. Burstein S (2005). PPAR-gamma: a nuclear receptor with affinity for cannabinoids. Life Sci 77: 1674-1684.
16. Cannich A, Wotjak CT, Kamprath K, Hermann H, Lutz B, Marsicano G (2004). CB1 cannabinoid receptors modulate kinase and phosphatase activity during extinction of conditioned fear in mice. Learn Mem 11: 625-632.
17. Carta G, Nava F, Gessa GL (1998). Inhibition of hippocampal acetylcholine release after acute and repeated Delta9-tetrahydrocannabinol in rats. Brain Res 809: 1-4.
18. Chen J, Paredes W, Lowinson JH, Gardner EL (1990). Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. Eur J Pharmacol 190: 259-262.
19. Connell K, Bolton N, Olsen D, Piomelli D, Hohmann AG (2006). Role of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia. Neurosci Lett 397: 180-184.
20. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR et al. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98: 9371-9376.
21. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384: 83-87.
22. Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V (2006). Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139: 1405-1415.
23. D'Amico M, Cannizzaro C, Preziosi P, Martire M (2004). Inhibition by anandamide and synthetic cannabimimetics of the release of [3H]D-aspartate and [3H]GABA from synaptosomes isolated from the rat hippocampus. Neurochem Res 29: 1553-1561.
24. de Miguel R, Romero J, Munoz RM, Garcia-Gil L, Gonzalez S, Villanua MA et al. (1998). Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic gamma-aminobutyric acid (GABA) inputs. Biochem Pharmacol 56: 1331-1338.
25. de Novellis V, Mariani L, Palazzo E, Vita D, Marabese I, Scafuro M et al. (2005). Periaqueductal grey CB1 cannabinoid and metabotropic glutamate subtype 5 receptors modulate changes in rostral ventromedial medulla neuronal activities induced by subcutaneous formalin in the rat. Neuroscience 134: 269-281.
26. Degroot A, Kofalvi A, Wade MR, Davis RJ, Rodrigues RJ, Rebola N et al. (2006). CB1 receptor antagonism increases hippocampal acetylcholine release: site and mechanism of action. Mol Pharmacol 70: 1236-1245.
27. Deutsch DG (2005). Design of on-target FAAH inhibitors. Chem Biol 12: 1157-1158.
28. Di S, Malcher-Lopes R, Marcheselli VL, Bazan NG, Tasker JG (2005). Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 146: 4292-4301.
29. Diana M, Melis M, Gessa GL (1998). Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur J Neurosci 10: 2825-2830.
30. Dinh TP, Freund TF, Piomelli D (2002). A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 121: 149-158.
31. Doherty J, Dingledine R (2003). Functional interactions between cannabinoid and metabotropic glutamate receptors in the central nervous system. Curr Opin Pharmacol 3: 46-53.
32. Domenici MR, Azad SC, Marsicano G, Schierloh A, Wotjak CT, Dodt HU et al. (2006). Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J Neurosci 26: 5794-5799.
33. Edsall SA, Knapp RJ, Vanderah TW, Roeske WR, Consroe P, Yamamura HI (1996). Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. NeuroReport 7: 593-596.
34. Egertova M, Cravatt BF, Elphick MR (2003). Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119: 481-496.
35. Egertova M, Giang DK, Cravatt BF, Elphick MR (1998). A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc R Soc Lond B Biol Sci 265: 2081-2085.
36. Eggan SM, Lewis DA (2007). Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex 17: 175-191.
37. Enna SJ, McCarson KE (2006). The role of GABA in the mediation and perception of pain. Adv Pharmacol 54: 1-27.
38. Fadda P, Scherma M, Spano MS, Salis P, Melis V, Fattore L et al. (2006). Cannabinoid self-administration increases dopamine release in the nucleus accumbens. NeuroReport 17: 1629-1632.
39. Ferraro L, Tomasini MC, Cassano T, Bebe BW, Siniscalchi A, O'Connor WT et al. (2001a). Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gamma-aminobutyric acid levels. J Neurosci Res 66: 298-302.
40. Ferraro L, Tomasini MC, Gessa GL, Bebe BW, Tanganelli S, Antonelli T (2001b). The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study. Cereb Cortex 11: 728-733.
41. Finn DP, Beckett SR, Richardson D, Kendall DA, Marsden CA, Chapman V (2004). Evidence for differential modulation of conditioned aversion and fear-conditioned analgesia by CB1 receptors. Eur J Neurosci 20: 848-852.
42. Finn DP, Chapman V (2004). Cannabinoids as analgesic agents: evidence from in vivo studies. Curr Neuropharmacol 2: 75-89.
43. Finn DP, Jhaveri MD, Beckett SR, Roe CH, Kendall DA, Marsden CA et al. (2003). Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology 45: 594-604.
44. Foldy C, Neu A, Jones MV, Soltesz I (2006). Presynaptic, activity-dependent 1modulation of cannabinoid type 1 receptor-mediated inhibition of GABA release. J Neurosci 26: 1465-1469.
45. Freiman I, Szabo B (2005). Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus. Neuroscience 133: 305-313.
46. French ED (1997). Delta(9)-tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett 226: 159-162.
47. French ED, Dillon K, Wu X (1997). Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. NeuroReport 8: 649-652.
48. Freund TF, Hajos N (2003). Excitement reduces inhibition via endocannabinoids. Neuron 38: 362-365.
49. Freund TF, Katona I, Piomelli D (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83: 1017-1066.
50. Fride E (2002). Endocannabinoids in the central nervous system - an overview. Prostaglandins Leukot Essent Fatty Acids 66: 221-233.
51. Galarreta M, Erdelyi F, Szabo G, Hestrin S (2004). Electrical coupling among irregular-spiking GABAergic interneurons expressing cannabinoid receptors. J Neurosci 24: 9770-9778.
52. Gentry C (1999). Where does it hurt? Wall Street J R6, published on October 18, 1999.
53. Gessa GL, Casu MA, Carta G, Mascia MS (1998). Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. Eur J Pharmacol 355: 119-124.
54. Gessa GL, Mascia MS, Casu MA, Carta G (1997). Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A. Eur J Pharmacol 327: R1-R2.
55. Gifford AN, Ashby Jr CR (1996). Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J Pharmacol Exp Ther 277: 1431-1436.
56. Gifford AN, Bruneus M, Gatley SJ, Volkow ND (2000). Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes. Br J Pharmacol 131: 645-650.
57. Gifford AN, Samiian L, Gatley SJ, Ashby Jr CR (1997). Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices. Eur J Pharmacol 324: 187-192.
58. Giuffrida A, Beltramo M, Piomelli D (2001). Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 298: 7-14.
59. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M et al. (2005). Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 102: 18620-18625.
60. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A et al. (2006). Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071: 10-23.
61. Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F et al. (2004). Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci 20: 441-458.
62. Gutierrez T, Nackley AG, Neely MH, Freeman KG, Edwards GL, Hohmann AG (2003). Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antinociception in models of acute and tonic nociception. Brain Res 987: 176-185.
63. Hajos N, Freund TF (2002). Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 43: 503-510.
64. Hajos N, Katona I, Naiem SS, Mackie K, Ledent C, Mody I et al. (2000). Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 12: 3239-3249.
65. Hajos N, Ledent C, Freund TF (2001). Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106: 1-4.
66. Hama AT, Urban MO (2004). Antihyperalgesic effect of the cannabinoid agonist WIN55, 212-2 is mediated through an interaction with spinal metabotropic glutamate-5 receptors in rats. Neurosci Lett 358: 21-24.
67. Haring M, Marsicano G, Lutz B, Monory K (2007). Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience 146: 1212-1219.
68. Hasanein P, Parviz M, Keshavarz M, Javanmardi K (2007). CB1 receptor activation in the basolateral amygdala produces antinociception in animal models of acute and tonic nociception. Clin Exp Pharmacol Physiol 34: 439-449.
69. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11: 563-583.
70. Hillard CJ, Jarrahian A (2003). Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol 140: 802-808.
71. Hillard CJ, Manna S, Greenberg MJ, DiCamelli R, Ross RA, Stevenson LA et al. (1999). Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 289: 1427-1433.
72. Hoffman AF, Lupica CR (2000). Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J Neurosci 20: 2470-2479.
73. Hohmann AG, Suplita II RL (2006). Endocannabinoid mechanisms of pain modulation. AAPS J 8: E693-E708.
74. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R et al. (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature 435: 1108-1112.
75. Holden JE, Pizzi JA (2003). The challenge of chronic pain. Adv Drug Deliv Rev 55: 935-948.
76. Howlett AC, Mukhopadhyay S, Shim JY, Welsh WJ (1999). Signal transduction of eicosanoid CB1 receptor ligands. Life Sci 65: 617-625.
77. Huang CC, Lo SW, Hsu KS (2001). Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol 532: 731-748.
78. Irving AJ, Coutts AA, Harvey J, Rae MG, Mackie K, Bewick GS et al. (2000). Functional expression of cell surface cannabinoid CB(1) receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons. Neuroscience 98: 253-262.
79. Jentsch JD, Verrico CD, Le D, Roth RH (1998). Repeated exposure to delta 9-tetrahydrocannabinol reduces prefrontal cortical dopamine metabolism in the rat. Neurosci Lett 246: 169-172.
80. Kathmann M, Weber B, Schlicker E (2001a). Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice. Naunyn Schmiedebergs Arch Pharmacol 363: 50-56.
81. Kathmann M, Weber B, Zimmer A, Schlicker E (2001b). Enhanced acetylcholine release in the hippocampus of cannabinoid CB(1) receptor-deficient mice. Br J Pharmacol 132: 1169-1173.
82. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81.
83. Katona I, Sperlagh B, Magloczky Z, Santha E, Kofalvi A, Czirjak S et al. (2000). GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 100: 797-804.
84. Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K et al. (1999). Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19: 4544-4558.
85. Katona I, Urban GM, Wallace M, Ledent C, Jung KM, Piomelli D et al. (2006). Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci 26: 5628-5637.
86. Katona IN, Rancz EA, Acsady L, Ledent C, Mackie K, Hajos N et al. (2001). Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci 21: 9506-9518.
87. Kofalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, Cunha RA et al. (2005). Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci 25: 2874-2884.
88. Lecca D, Cacciapaglia F, Valentini V, Di Chiara G (2006). Monitoring extracellular dopamine in the rat nucleus accumbens shell and core during acquisition and maintenance of intravenous WIN 55,212-2 self-administration. Psychopharmacology (Berl) 188: 63-74.
89. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F et al. (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401-404.
90. Lichtman AH, Cook SA, Martin BR (1996). Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 276: 585-593.
91. Lichtman AH, Martin BR (1997). The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats. Pharmacol Biochem Behav 57: 7-12.
92. Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR (1988). Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther 247: 1046-1051.
93. LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D (2005). The search for the palmitoylethanolamide receptor. Life Sci 77: 1685-1698.
94. Lu XR, Ong WY, Mackie K (1999). A light and electron microscopic study of the CB1 cannabinoid receptor in monkey basal forebrain. J Neurocytol 28: 1045-1051.
95. Mailleux P, Parmentier M, Vanderhaeghen JJ (1992). Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligonucleotides. Neurosci Lett 143: 200-204.
96. Mailleux P, Vanderhaeghen JJ (1992). Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48: 655-668.
97. Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M et al. (2006). Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 316: 969-982.
98. Makara JK, Mor M, Fegley D, Szabo SI, Kathuria S, Astarita G et al. (2005). Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 8: 1139-1141.
99. Malone DT, Taylor DA (1999). Modulation by fluoxetine of striatal dopamine release following delta9-tetrahydrocannabinol: a microdialysis study in conscious rats. Br J Pharmacol 128: 21-26.
100. Manning BH, Martin WJ, Meng ID (2003). The rodent amygdala contributes to the production of cannabinoid-induced antinociception. Neuroscience 120: 1157-1170.
101. Manning BH, Merin NM, Meng ID, Amaral DG (2001). Reduction in opioid- and cannabinoid-induced antinociception in rhesus monkeys after bilateral lesions of the amygdaloid complex. J Neurosci 21: 8238-8246.
102. Marinelli S, Di Marzo V, Florenzano F, Fezza F, Viscomi MT, van der Stelt M et al. (2007). N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology 32: 298-308.
103. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A et al. (2003). CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302: 84-88.
104. Marsicano G, Lutz B (1999). Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11: 4213-4225.
105. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG et al. (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530-534.
106. Martin WJ, Coffin PO, Attias E, Balinsky M, Tsou K, Walker JM (1999). Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res 822: 237-242.
107. Martin WJ, Lai NK, Patrick SL, Tsou K, Walker JM (1993). Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Res 629: 300-304.
108. Martin WJ, Tsou K, Walker JM (1998). Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci Lett 242: 33-36.
109. Matsuda LA, Bonner TI, Lolait SJ (1993). Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327: 535-550.
110. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
111. McDonald AJ, Mascagni F (2001). Localization of the CB1 type cannabinoid receptor in the rat basolateral amygdala: high concentrations in a subpopulation of cholecystokinin-containing interneurons. Neuroscience 107: 641-652.
112. McFarland MJ, Barker EL (2004). Anandamide transport. Pharmacol Ther 104: 117-135.
113. Mechoulam R, Gaoni Y (1967). Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86: 1646-1647.
114. Melis M, Gessa GL, Diana M (2000). Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain. Prog Neuropsychopharmacol Biol Psychiatry 24: 993-1006.
115. Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL (2004). Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 24: 53-62.
116. Mendiguren A, Pineda J (2006). Systemic effect of cannabinoids on the spontaneous firing rate of locus coeruleus neurons in rats. Eur J Pharmacol 534: 83-88.
117. Meng ID, Johansen JP (2004). Antinociception and modulation of rostral ventromedial medulla neuronal activity by local microinfusion of a cannabinoid receptor agonist. Neuroscience 124: 685-693.
118. Meng ID, Manning BH, Martin WJ, Fields HL (1998). An analgesia circuit activated by cannabinoids. Nature 395: 381-383.
119. Millan MJ (1999). The induction of pain: an integrative review. Prog Neurobiol 57: 1-164.
120. Millan MJ (2002). Descending control of pain. Prog Neurobiol 66: 355-474.
121. Misner DL, Sullivan JM (1999). Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. J Neurosci 19: 6795-6805.
122. Moldrich G, Wenger T (2000). Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides 21: 1735-1742.
123. Monhemius R, Azami J, Green DL, Roberts MH (2001). CB1 receptor mediated analgesia from the nucleus reticularis gigantocellularis pars alpha is activated in an animal model of neuropathic pain. Brain Res 908: 67-74.
124. Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R et al. (2006). The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51: 455-466.
125. Mu J, Zhuang SY, Kirby MT, Hampson RE, Deadwyler SA (1999). Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture. J Pharmacol Exp Ther 291: 893-902.
126. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65.
127. Muntoni AL, Pillolla G, Melis M, Perra S, Gessa GL, Pistis M (2006). Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons. Eur J Neurosci 23: 2385-2394.
128. Naderi N, Shafaghi B, Khodayar MJ, Zarindast MR (2005). Interaction between gamma-aminobutyric acid GABAB and cannabinoid CB1 receptors in spinal pain pathways in the rat. Eur J Pharmacol 414: 159-164.
129. Nakazi M, Bauer U, Nickel T, Kathmann M, Schlicker E (2000). Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol 361: 19-24.
130. Nava F, Carta G, Colombo G, Gessa GL (2001). Effects of chronic Delta(9)-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze. Neuropharmacology 41: 392-399.
131. Neto FL, Ferreira-Gomes J, Castro-Lopes JM (2006). Distribution of GABA receptors in the thalamus and their involvement in nociception. Adv Pharmacol 54: 29-51.
132. Neu A, Foldy C, Soltesz I (2007). Postsynaptic origin of CB1-dependent tonic inhibition of GABA release at cholecystokinin-positive basket cell to pyramidal cell synapses in the CA1 region of the rat hippocampus. J Physiol 578: 233-247.
133. Ng Cheong Ton JM, Gerhardt GA, Friedemann M, Etgen AM, Rose GM, Sharpless NS et al. (1988). The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study. Brain Res 451: 59-68.
134. Nyiri G, Cserep C, Szabadits E, Mackie K, Freund TF (2005a). CB1 cannabinoid receptors are enriched in the perisynaptic annulus and on preterminal segments of hippocampal GABAergic axons. Neuroscience 136: 811-822.
135. Nyiri G, Szabadits E, Cserep C, Mackie K, Shigemoto R, Freund TF (2005b). GABAB and CB1 cannabinoid receptor expression identifies two types of septal cholinergic neurons. Eur J Neurosci 21: 3034-3042.
136. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA et al. (2006). Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann NY Acad Sci 1074: 514-536.
137. Ong WY, Mackie K (1999). A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain. Neuroscience 92: 1177-1191.
138. Oropeza VC, Mackie K, Van Bockstaele EJ (2007). Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex. Brain Res 1127: 36-44.
139. Oropeza VC, Page ME, Van Bockstaele EJ (2005). Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Res 1046: 45-54.
140. Palazzo E, de Novellis V, Petrosino S, Marabese I, Vita D, Giordano C et al. (2006). Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. Eur J Neurosci 24: 2011-2020.
141. Palazzo E, Marabese I, de Novellis V, Oliva P, Rossi F, Berrino L et al. (2001). Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception. Neuropharmacology 40: 319-326.
142. Pertwee RG (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74: 129-180.
143. Pertwee RG (1999). Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6: 635-664.
144. Pertwee RG (2001). Cannabinoid receptors and pain. Prog Neurobiol 63: 569-611.
145. Petrosino S, Palazzo E, de Novellis V, Bisogno T, Rossi F, Maione S et al. (2007). Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 52: 415-422.
146. Pillolla G, Melis M, Perra S, Muntoni AL, Gessa GL, Pistis M (2007). Medial forebrain bundle stimulation evokes endocannabinoid-mediated modulation of ventral tegmental area dopamine neuron firing in vivo. Psychopharmacology (Berl) 191: 843-853.
147. Pisanu A, Acquas E, Fenu S, Di Chiara G (2006). Modulation of delta(9)-THC-induced increase of cortical and hippocampal acetylcholine release by micro opioid and D(1) dopamine receptors. Neuropharmacology 50: 661-670.
148. Pistis M, Porcu G, Melis M, Diana M, Gessa GL (2001). Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. Eur J Neurosci 14: 96-102.
149. Poddar MK, Dewey WL (1980). Effects of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes. J Pharmacol Exp Ther 214: 63-67.
150. Ralston III HJ (1991). Local circuitry of the somatosensory thalamus in the processing of sensory information. Prog Brain Res 87: 13-28.
151. Riegel AC, Lupica CR (2004). Independent presynaptic and post-synaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. J Neurosci 24: 11070-11078.
152. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240-244.
153. Robbe D, Alonso G, Duchamp F, Bockaert J, Manzoni OJ (2001). Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J Neurosci 21: 109-116.
154. Rodriguez De Fonseca F, Gorriti MA, Bilbao A, Escuredo L, Garcia-Segura LM, Piomelli D et al. (2001). Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia. Neurotox Res 3: 23-35.
155. Ryberg E, Vu HK, Larsson N, Groblewski T, Hjorth S, Elebring T et al. (2005). Identification and characterisation of a novel splice variant of the human CB1 receptor. FEBS Lett 579: 259-264.
156. Saario SM, Poso A, Juvonen RO, Jarvinen T, Salo-Ahen OM (2006). Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system. J Med Chem 49: 4650-4656.
157. Saario SM, Savinainen JR, Laitinen JT, Jarvinen T, Niemi R (2004). Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem Pharmacol 67: 1381-1387.
158. Schlicker E, Timm J, Zentner J, Gothert M (1997). Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn Schmiedebergs Arch Pharmacol 356: 583-589.
159. Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, Le Fur G et al. (1995). An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 270: 3726-3731.
160. Siegling A, Hofmann HA, Denzer D, Mauler F, De Vry J (2001). Cannabinoid CB1 receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 415: R5-R7.
161. Solinas M, Justinova Z, Goldberg SR, Tanda G (2006). Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem 98: 408-419.
162. Sun Y, Alexander SP, Kendall DA, Bennett AJ (2006). Cannabinoids and PPARalpha signalling. Biochem Soc Trans 34: 1095-1097.
163. Suplita II RL, Farthing JN, Gutierrez T, Hohmann AG (2005). Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla. Neuropharmacology 49: 1201-1209.
164. Szabo B, Muller T, Koch H (1999). Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. J Neurochem 73: 1084-1089.
165. Szabo B, Wallmichrath I, Mathonia P, Pfreundtner C (2000). Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience 97: 89-97.
166. Tanda G, Loddo P, Di Chiara G (1999). Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. Eur J Pharmacol 376: 23-26.
167. Tanda G, Pontieri FE, Di Chiara G (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276: 2048-2050.
168. Trettel J, Fortin DA, Levine ES (2004). Endocannabinoid signalling selectively targets perisomatic inhibitory inputs to pyramidal neurones in juvenile mouse neocortex. J Physiol 556: 95-107.
169. Trettel J, Levine ES (2002). Cannabinoids depress inhibitory synaptic inputs received by layer 2/3 pyramidal neurons of the neocortex. J Neurophysiol 88: 534-539.
170. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998). Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83: 393-411.
171. Tsou K, Mackie K, Sanudo-Pena MC, Walker JM (1999). Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience 93: 969-975.
172. Tzavara ET, Perry KW, Rodriguez DE, Bymaster FP, Nomikos GG (2001). The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur J Pharmacol 426: R3-R4.
173. Tzavara ET, Wade M, Nomikos GG (2003a). Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J Neurosci 23: 9374-9384.
174. Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP et al. (2003b). The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 138: 544-553.
175. Ueda N, Puffenbarger RA, Yamamoto S, Deutsch DG (2000). The fatty acid amide hydrolase (FAAH). Chem Phys Lipids 108: 107-121.
176. Ulrich D, Huguenard JR (1997). GABA(A)-receptor-mediated rebound burst firing and burst shunting in thalamus. J Neurophysiol 78: 1748-1751.
177. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K et al. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329-332.
178. Vaughan CW, Connor M, Bagley EE, Christie MJ (2000). Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 57: 288-295.
179. Vaughan CW, McGregor IS, Christie MJ (1999). Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. Br J Pharmacol 127: 935-940.
180. Verrico CD, Jentsch JD, Roth RH (2003a). Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats. Synapse 49: 61-66.
181. Verrico CD, Jentsch JD, Dazzi L, Roth RH (2003b). Systemic, but not local, administration of cannabinoid CB1 receptor agonists modulate prefrontal cortical acetylcholine efflux in the rat. Synapse 48: 178-183.
182. Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC (1999). Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 96: 12198-12203.
183. Welch SP, Huffman JW, Lowe J (1998). Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther 286: 1301-1308.
184. Wenger T, Moldrich G, Furst S (2003). Neuromorphological background of cannabis addiction. Brain Res Bull 61: 125-128.
185. Wotherspoon G, Fox A, McIntyre P, Colley S, Bevan S, Winter J (2005). Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135: 235-245.
186. Wu X, French ED (2000). Effects of chronic delta9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment. Neuropharmacology 39: 391-398.
187. Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D (2003). Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 17: 2750-2754.
188. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999). Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96: 5780-5785.